



Press release

Invitation to BioArctic's Capital Markets Day 2025 in Stockholm

Stockholm, March 27, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) is pleased to welcome investors, analysts and financial media to a Capital Markets Day on June 2, 2025. The Capital Markets Day will be held at Helio GT30, Grev Turegatan 30 in Stockholm, and will be broadcast live online. The event will begin at 10:30 AM and is expected to last until 3:30 PM, including lunch.

The Capital Markets Day will provide an update on the company's strategy and vision for 2030, as well as in-depth insight into the company's operations. Presentations will be given in English by members of the Executive Management Team and participants will be able to ask questions.

Registration of interest to participate in the Capital Markets Day is via the following link:
<https://bioarctic.events.inderes.com/cmd-2025>.

The number of seats for those who wish to attend on site are limited and participation is not confirmed until a confirmation email has been received verifying participation. The agenda and more detailed information will be published on BioArctic's website before the event and by email to registered participants. Presentation materials and a recording of the Capital Markets Day will be available afterwards on BioArctic's website.

The information was released for public disclosure, through the agency of the contact person below, on March 27, 2025, at 10:00 AM CET.

For further information, please contact:

Oskar Bosson, VP Communications and IR

Phone: +46 70 410 71 80

E-mail: oskar.bosson@bioarctic.com

Charlotte af Klercker, Senior Director Sustainability and Communications

Telephone: +46 73 515 09 70

E-mail: charlotte.afklercker@bioarctic.com

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.